[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-371840-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-371840-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","cancer-disparities-in-lean-vs-non-lean-mash-insight-from-a-national-inpatient-sample","Cancer disparities in lean vs. non-lean MASH - insight from a national inpatient sample","","Objective investigates cancer disparities between lean and non-lean metabolic dysfunction-associated steatohepatitis (MASH) by analyzing the prevalence of 18 common cancers within a large U.S. cohort. Methods use a retrospective cohort design with the National Inpatient Sample (2016–2020), applying weighted data, categorizing patients by BMI during hospitalization, and excluding alternative etiologies. Outcomes assess composite and individual cancer prevalence with multivariable logistic regression. Results report higher lung, colon, kidney, liver, and cervical cancer odds among lean MASH hospitalizations, alongside lower endometrial cancer odds. Conclusion links lean MASH hospitalizations to higher odds of multiple cancers and indicates BMI alone may not capture oncologic risk.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/cancer-disparities-in-lean-vs-non-lean-mash-insight-from-a-national-inpatient-sample/371840/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/cancer-disparities-in-lean-vs-non-lean-mash-insight-from-a-national-inpatient-sample/371840.png","ImageObject",300,407,{"name":42,"@type":43},"Aldword","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What study objective does this research address?","Question",{"text":63,"@type":64},"To investigate cancer disparities between lean and non-lean MASH by analyzing the prevalence of 18 common cancers in a large U.S. cohort.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were patients classified as lean or non-lean?",{"text":68,"@type":64},"Patients were categorized based on BMI during hospitalization, using a retrospective approach and excluding alternative etiologies via validated algorithms.",{"name":70,"@type":61,"acceptedAnswer":71},"Which cancers showed higher odds in lean MASH hospitalizations?",{"text":72,"@type":64},"Lean MASH hospitalizations had higher odds for lung, colon, kidney, liver, and cervical cancers, as well as non-Hodgkin’s lymphoma.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},371840,1790219422,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":116,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},2336478940917,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Ezeani et al. BMCGastroenterology (2025) 25:659 [https://doi.org/10.1186/s12876-025-04187-1](https://doi.org/10.1186/s12876-025-04187-1)  \nBMC Gastroenterology  \nRESEARCH Open Access  \nCancer disparities in lean vs. non-lean MASH:  insight from a national inpatient sample  \nChukwunonso Ezeani 1, Chidiebele Omaliko2, Petr Protiva3, Yazan A. Al-Ajlouni4, Gyanprakash Ketwaroo3 and Basile Njei3*  \nAbstract  \nObjective To investigate cancer disparities between lean (BMI \u003C 25 kg/m²; \u003C 23 kg/m² for Asians) and non-lean metabolic dysfunction-associated steatohepatitis (MASH) by analyzing the prevalence of the 18 most common cancers in a large U. S. cohort.  \nMethods This retrospective cohort study utilized the National Inpatient Sample (2016–2020) with weighted data to project findings to the general population. Patients were categorized as lean or non-lean based on BMI during hospitalization, excluding alternative etiologies via validated algorithms. Outcomes included composite cancer prevalence (primary) and individual cancer prevalence (secondary) . Multivariable logistic regression was applied to assess differences.  \nResults Among 34,955,252 U. S. hospitalizations, 539,275 patients had MASH (mean age: 64 years for lean vs. 58.8 years for non-lean; >60% female) . Lean MASH hospitalizations had higher odds of lung (aOR 1. 76, CI 1.33–2. 10,  \nP \u003C 0. 001), colon (aOR 1. 23, CI 1.02–1.48, P = 0 . 027), kidney (aOR 1. 27, CI 1.10–1.44, P = 0 . 001), liver (aOR 1. 21, CI 1.12– 1. 31, P \u003C 0. 001), and cervical cancers (aOR 3 . 25, CI 1.07–9. 86, P = 0 . 037), as well as non-Hodgkin’s lymphoma (aOR 1. 28, CI 1.08–1. 51, P = 0 . 004), but lower odds of endometrial cancer (aOR 0 . 35, CI 0.25–0. 50, P \u003C 0. 001) .  \nConclusion Lean MASH hospitalizations are linked to higher odds of several cancers despite lower BMI, underscoring the need for a nuanced understanding of cancer risks in MASH. BMI alone may not fully capture oncologic risk in this population.  \nKeywords Metabolic-dysfunction Associated Steatohepatitis, Metabolic-dysfunction Associated Steatotic Liver Disease, Cancer, Mortality  \n*Correspondence:  \nBasile Njei  \n[basile.njei@yale.edu](basile.njei@yale.edu)  \n1Department of Internal medicine, Baton Rouge General Medical Center, Baton Rouge, LA 70809, USA  \n2Department of Internal Medicine, Brookdale University Hospital, Brooklyn, NY 11212, USA  \n3Division of Digestive Diseases, International Medicine Program (Section of Digestive Diseases), Yale School of Medicine, Yale University, New Haven, CT 06510, USA  \n4Department of Rehabilitation, Montefiore Hospital, Bronx, NY 10466, USA  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/l](http://creativecommons.org/l)icenses/by/4.0/.  \nEzeani et al. BMC Gastroenterology (2025) 25:659  \nKey messages  \nWhat is already known on this topic:  \nMetabolic dysfunction-associated steatohepatitis (MASH) is a known risk factor for liver and extrahepatic cancers, predominantly among nonlean individuals. Lean MASH, a metabolic condition without obesity, presents a paradox with unclear cancer risk profiles that have been minimally explored in Western populations.  \nWhat this study adds:  \nThis study identifi","cbCaiiz1pu7x3F6Y","https://ap.wps.com/l/cbCaiiz1pu7x3F6Y","pdf",1332708,"English","# Abstract\n## Objective\n## Methods\n## Results\n## Conclusion\n# Introduction\n## Background on MASLD/MASH terminology\n## Prior evidence linking MASH, metabolic factors, and cancer","[{\"question\":\"What study objective does this research address?\",\"answer\":\"To investigate cancer disparities between lean and non-lean MASH by analyzing the prevalence of 18 common cancers in a large U.S. cohort.\"},{\"question\":\"How were patients classified as lean or non-lean?\",\"answer\":\"Patients were categorized based on BMI during hospitalization, using a retrospective approach and excluding alternative etiologies via validated algorithms.\"},{\"question\":\"Which cancers showed higher odds in lean MASH hospitalizations?\",\"answer\":\"Lean MASH hospitalizations had higher odds for lung, colon, kidney, liver, and cervical cancers, as well as non-Hodgkin’s lymphoma.\"}]","Cancer disparities in lean vs. non-lean MASH - insight from a national inpatient sample | PDF",1790192997,23,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d98643fb35a661ed5616e38becb50ed1.webp",983,1310,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2999b12906192a12c48f4e61f48a61c5.webp",982,1309,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bf55aa3e2afb29f7800c76f927e6e7b5.webp",981,1308,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b8a5cc7b5a1aa0b569a6119abc2e1d60.webp",980,1306]